Lung Cancer Mutation Panel 3- EGFR Sequencing with ALK-1 IHC & ROS-1 by FISH

EGFR sequencing is a laboratory method used to read the genetic code of the EGFR gene in cancer cells. This method can identify mutations in the EGFR gene, which can be targeted by specific treatments.

ALK-1 IHC is a technique used to identify ALK gene rearrangements in cancer cells. An ALK-1 antibody is used to bind to the ALK protein in cells where the gene is rearranged and overactive.

ROS-1 FISH is a laboratory method used to identify rearrangements in the ROS-1 gene in cancer cells. This technique uses fluorescent probes that bind to the ROS-1 gene if it is rearranged.

A mutation in one of these genes means that your cancer may be driven by this mutation. This could impact your treatment options, as certain targeted therapies are designed to target these specific genetic changes.

Most mutations found in lung cancer are acquired during a person's lifetime and are not inherited. This means that these mutations are not typically passed down from parents to their children.

Yes, the results of this test can significantly impact your treatment options. If a specific mutation is identified, targeted therapies can be used to specifically treat your type of cancer.

Yes, the genetic makeup of a tumor can change over time, particularly in response to treatment. Your doctor may recommend repeat testing if your cancer progresses or if you become resistant to treatment.

This test is performed on a sample of your blood or tissue. Your doctor will provide instructions on how and when the sample will be collected.

It typically takes about 7-10 days to receive the results of this test. However, the timing can vary depending on the lab.

There may be slight risks associated with the sample collection process. If a tissue sample is taken, you may experience minor discomfort, bleeding, or infection at the biopsy site.

A positive result indicates the presence of a mutation in one or more of the tested genes. This information will be used by your healthcare provider to tailor your treatment plan.

The coverage of this test depends on your health insurance policy. Please check with your insurance provider for specific details.

While the results of this test are usually accurate, no test is 100% definitive. You should discuss your results and their implications with your healthcare provider.

This test is primarily used to identify targetable mutations in your cancer. Other tests may be more suitable for monitoring disease progression.

Yes, this test can help predict your response to certain targeted therapies. However, other factors may also influence your response to treatment.

While this panel tests for mutations in the EGFR, ALK, and ROS-1 genes, it does not cover all possible mutations that can occur in lung cancer. There are many other mutations which may not be covered by this panel.

A negative result means that the tested mutations were not detected in your sample. However, it does not rule out the presence of other mutations not covered by this test or that your cancer is not driven by a genetic mutation.

The frequency of this test will depend on your individual circumstances. Your healthcare provider will give you specific guidance based on your condition and response to treatment.

This test requires specific expertise and equipment, and may not be available at all labs. It is important to have this test performed at a specialized lab with experience in genetic testing for cancer.

Lifestyle changes or medications generally do not influence the results of this genetic test. However, it’s always important to inform your doctor about any medications you are taking or lifestyle changes you’ve made.

This test is not designed to determine carrier status as most mutations linked with lung cancer are not hereditary. They are acquired mutations, which occur during a person’s lifetime.

The Lung Cancer Mutation Panel 3 is generally very reliable in detecting the specific mutations it is designed to find. However, the sensitivity and specificity can depend on the type and quality of the sample used for the test.

If a mutation is detected, targeted therapies designed to interfere with the function of the mutated proteins may be available. These therapies may be more effective and cause fewer side effects than traditional chemotherapy.

Understanding the genetic makeup of your cancer can help your doctor choose treatments that are more likely to be effective. It can also help identify clinical trials for which you may be eligible.

Your doctor may recommend repeating the test if your cancer progresses, if there is a change in your condition, or if you develop resistance to a targeted therapy.